Superiority Claims Based On Drug Delivery System Fail DDMAC Test
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire overreached in claiming that the formulations for its ulcerative colitis drugs Lialda and Pentasa gave them an advantage, FDA says.